Chung Eric, Lee Joe, Liu Chia Chu, Taniguchi Hisanori, Zhou Hui Liang, Park Hyun Jun
Department of Urology, Princess Alexandra Hospital, University of Queensland, Brisbane, Australia.
Department of Urology, Macquarie University Hospital, Sydney, Australia.
World J Mens Health. 2021 Jan;39(1):1-8. doi: 10.5534/wjmh.200077. Epub 2020 Jun 2.
Published literature shows low intensity extracorporeal shock wave therapy (LIESWT) and low intensity pulsed ultrasound (LIPUS) therapy to improve erectile function and penile hemodynamic by inducing neovascularisation and promoting tissue regeneration. Key opinion leaders across the Asia Pacific region attended the recent biennial meeting of the Asia Pacific Society for Sexual Medicine in Australia, and presented the current evidence on LIESWT and LIPUS for erectile dysfunction (ED). The clinical findings were internally discussed, and the quality of evidence was graded based on the Oxford Centre for Evidence-Based Medicine recommendations. Existing literature supports the use of LIESWT and LIPUS in men with ED, with many clinical studies reported encouraging results with improved erectile function, good safety profile and short-term durability. However, controversial exists due to sampling heterogeneity, non-standardised treatment protocol and lack of large multiinstitutional studies. There is a need to better define which subgroup of ED population is best-suited, and specific treatment protocol to optimise shock wave energy delivery. More stringent and larger multi-institutional randomised placebo-controlled trials are warranted before clinical adoption of LIESWT and LIPUS as the new standard of care for men with ED.
已发表的文献表明,低强度体外冲击波疗法(LIESWT)和低强度脉冲超声(LIPUS)疗法可通过诱导新血管形成和促进组织再生来改善勃起功能和阴茎血流动力学。亚太地区的主要意见领袖参加了最近在澳大利亚举行的亚太性医学协会两年一次的会议,并展示了关于LIESWT和LIPUS治疗勃起功能障碍(ED)的现有证据。对临床研究结果进行了内部讨论,并根据牛津循证医学中心的建议对证据质量进行了分级。现有文献支持在ED男性中使用LIESWT和LIPUS,许多临床研究报告了令人鼓舞的结果,包括勃起功能改善、良好的安全性和短期持久性。然而,由于样本异质性、治疗方案不标准化以及缺乏大型多机构研究,存在争议。有必要更好地确定哪种ED人群亚组最适合,以及优化冲击波能量传递的具体治疗方案。在将LIESWT和LIPUS临床应用于ED男性作为新的护理标准之前,需要进行更严格、更大规模的多机构随机安慰剂对照试验。